Status:
RECRUITING
New AI-based Technologies in Nuclear Medicine
Lead Sponsor:
Azienda USL Reggio Emilia - IRCCS
Conditions:
Patients Undergoing PET/CT Investigation or Nuclear Medicine Therapy
Eligibility:
All Genders
18-90 years
Brief Summary
The study aims to identify and predict radiopharmaceutical extravasation events using new semi-quantitative parameters and machine learning models. It involves dose rate measurements to develop metric...
Detailed Description
This is a descriptive, observational, non-profit study aimed at detecting and predicting extravasation events during the administration of radiopharmaceuticals for diagnostic and therapeutic purposes ...
Eligibility Criteria
Inclusion
- patients undergoing PET/CT scans or therapeutic treatments with radiopharmaceuticals labelled with alpha or beta emitting nuclides
Exclusion
- patients whose clinical or psychological conditions do not allow for their involvement
Key Trial Info
Start Date :
July 30 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 31 2026
Estimated Enrollment :
1500 Patients enrolled
Trial Details
Trial ID
NCT07174089
Start Date
July 30 2021
End Date
March 31 2026
Last Update
September 15 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Azienda USL IRCCS di Reggio Emilia
Reggio Emilia, Italy